June 30

Hertzelia, IL

Receive PMWC updates & offers by email

First:
Last:
Email:

Track 2 Judges & Screening Committee

Abraham Ludomirski

Abraham Ludomirski, M.D., Founder, Vitalife Life Sciences Fund

Abraham Ludomirski, M.D., Founder, Vitalife Life Sciences Fund

Dr. Abraham Ludomirski is an internationally renowned physician with more than 20 years experience in life sciences, with particular expertise in medical devices, health homecare, and biomaterials. Dr. Ludomirski founded and developed the SafeKeeping Company (remote monitoring of high risk pregnancies), which was later acquired by a leading corporation active in this area. He has been a consultant to a number of Israeli and American venture capital funds and large medical technology companies, including GE Medical, ATL - Philips, Medison, Matria Healthcare, and QED Technologies. He has instructed and has led several start-ups through the process of raising capital, creating strategic partnerships, establishing joint ventures, and successfully achieving regulatory clearances. He currently serves as Director or Chairman of BioControl Medical, Deep Breeze, DIR Technologies, EndoSpan, MST, Pocared Diagnostics, Recro Pharma, and Sensible Medical Innovations. Previously, Dr. Ludomirski served as Chairman of Sightline Technologies (sold to Stryker) and MediGuide (sold to St. Jude). Dr. Ludomirski earned his M.D. at the Sackler Tel-Aviv University Medical School and specialized in OB-GYN. Following medical school, he completed his fellowship at the University of Pennsylvania in maternal fetal medicine. He was one of the founders of the fetal surgery program and established an internationally known fetal blood-sampling registry. He served as the Director of the Maternal Fetal Medicine Division and as a Professor of OB-GYN at Temple University Medical School for three years. Dr. Ludomirski has published numerous articles in peer-reviewed journals and has lectured around the world. He has also served as a reviewer for several leading medical journals.

Afton Vechery

Afton Vechery, Head of the Personalized Medicine Initiative, Great Point Partners

Afton Vechery, Head of the Personalized Medicine Initiative, Great Point Partners

Afton Vechery is the Head of the personalized medicine initiative within Great Point Partners II’s Heath Care Private Equity Group. Since joining in 2011, Afton has focused the development of Great Point’s strategy and pipeline development of “profitable” personal medicine companies for GPP II and is a board observer for two of Great Point’s portfolio companies. Before joining Great Point, Afton studied neuroscience, business and entrepreneurship at Wake Forest University where she worked in the Institute of Regenerative Medicine’s Wet Lab space and founded an early revenue model for a biomaterials regenerative medicine company which evolved into Keratin Cosmetic Sciences. She has also worked under Dr. David Edwards at Le Labortoire innovation laboratory.

Alexis Borisy

Alexis Borisy, Partner, Third Rock Ventures

Alexis Borisy, Partner, Third Rock Ventures

Alexis Borisy is a successful biotechnology entrepreneur with 20 years of experience building and operating innovative science based organizations such as Foundation Medicine, Blueprint Medicines, and CombinatoRx. Alexis is a Partner at Third Rock Ventures, where he focuses on the formation, development and strategy of new companies. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Alexis was honored as the MIT Technology Review Innovator of the Year.

Anat Naschitz

Anat Naschitz, Managing Director, OrbiMed

Anat Naschitz, Managing Director, OrbiMed

Anat Naschitz, LLB, MBA, is a Managing Director at . She has over 17 years of healthcare experience. Anat spent seven years with McKinsey & Company in London, where she was an Associate Partner, managing strategy and M&A projects for senior management of the world's preeminent pharmaceutical and biotechnology companies. Among other accomplishments, Anat led pharmaceutical spinout work resulting in the creation of two European biotech companies, which subsequently had IPOs for over $1 billion. Anat then joined Apax Partners, where she focused on life sciences investments. Subsequently Anat served as a director/advisor to the boards of life science companies and investors. She earned her MBA at INSEAD and her LLB at Tel Aviv University.

Andrew Kurtz

Andrew Kurtz, Ph.D., Program Director, Small Business Innovation Research Development Center, NCI

Andrew Kurtz, Ph.D., Program Director, Small Business Innovation Research Development Center, NCI

Dr. Kurtz has been a Program Director in the Small Business Innovation Research Development Center at the National Cancer Institute. His management portfolio includes projects focused on early-stage cancer drug development, including small molecules, biologics, and novel multifunctional therapeutics based on nanotechnology. Previously, Dr. Kurtz was an AAAS Science and Technology Policy Fellow at the NIH, during which time he served on the management team of The Cancer Genome Atlas Pilot Project. Dr. Kurtz received a PhD in Biochemistry & Molecular Biology from The University of Texas Medical Branch at Galveston.

Jack Young

Jack Young, Director, Qualcomm Life Fund

Jack Young, Director, Qualcomm Life Fund

Jack heads up the $100M Qualcomm Life Fund (QLF) at Qualcomm Ventures, which was recently ranked as one of the most prolific venture investors in the digital health sector. His investment interests are focused in the areas of digital technologies and wireless health services and applications including: wellness and fitness, chronic disease management, aging in place, transitional care, clinical trials and telehealth/telemedicine. Jack currently serves as a board observer at QLF portfolio companies including Airstrip, AliveCor, ClearCare, goBalto and Telcare. In addition, he serves as a board observer at Jana, Modern Video, uCIRRUS, Validity and Visage Mobile. Prior to Qualcomm Ventures, Jack was EVP and US Country Manager at ZTE who helped establish the company’s US market presence. He was a sales and marketing executive at Nokia following the acquisition of Amber Networks where he was founding AVP of marketing. Early in his career, he held marketing and business development positions at 3Com, GDC, and Nortel. Jack earned a MSEE from University of Calgary and a MBA from McGill University.

John Steuart

John Steuart, Managing director, Prolog Ventures

John Steuart, Managing director, Prolog Ventures

John has more than 25 years of experience managing healthcare and technology venture funds and companies. Prior to Prolog, he was a co-founder and managing director of Claremont Creek Ventures. He also served as the CFO of two venture-backed public companies that were acquired by United Airlines New Ventures. He began his investment career at Alafi Capital. John earned a bachelor’s degree in economics from UC Berkeley, where he serves on the Advisory Boards for the Lester Center of Entrepreneurship and Center for Entrepreneurship and Technology.

KT Moortgat

KT Moortgat, Startup Consultant former Partner, Mohr Davidow Ventures

KT Moortgat, Startup Consultant former Partner, Mohr Davidow Ventures

KT’s career has focused on the early stage translation and commercialization of disruptive fundamental technologies. KT has supported healthcare startups in business development, commercial partnerships, product marketing, as well as assisted in recruiting young technical talent. Formerly a member of the Mohr Davidow venture capital investment team, she led initiatives fostering the commercialization of technologies originating in universities and national labs; including medical diagnostics, mental health, synthetic biology, and clean energy. Prior to joining Mohr Davidow, KT founded and directed the Center for BioEntrepreneurship, at UC San Francisco and the QB3 Institute. The Center established UCSF’s hub for training, mentoring, and networking for entrepreneurial scientists and clinicians, and engaged over 1000 participants annually. At the University of Southern California’s Stevens Institute for Innovation, KT was a member of the Board of Councilors in 2011-2012. KT was awarded a Sloan Postdoctoral Fellowship at UC San Francisco. She holds a doctorate in Biophysics for research conducted at the Salk Institute and Scripps Institution of Oceanography, and Master’s and Bachelor’s degrees in Physics from UC San Diego and UC Berkeley, respectively.

Patrick F. Terry

Patrick F. Terry, Chairman, Grey Group Ventures, Inc.

Patrick F. Terry, Chairman, Grey Group Ventures, Inc.

Patrick is a serial entrepreneur who has founded a series of philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. He co-founded Genomic Health [NASDAQ: GHDX] and was former Director at the pioneering personalized medicine company based in California. He has published dozens of peer-reviewed scientific papers, articles, and book chapters in the fields of genetics, rare disease, and translational medicine. Some of his activities included leadership positions on numerous trade associations, professional societies, corporate boards, and federal advisory bodies. He has experience coordinating genetics research, conducting research on rare diseases, and managing a life sciences patent portfolio. He has received many honors and awards in the business and scientific communities in the U.S. and internationally. He is currently a Director at MeMed Diagnostics (Israel-based Company), PXE International, and GRAND Therapeutics. He has also helped found the following organizations: US Personalized Medicine Coalition, 21st Century Medicine Coalition, European Personalized Medicine Diagnostic Association, PXE International, Genetic Alliance BioBank, BioLogos Foundation, Coalition for Research on the Eye, International Genetic Alliance, and GRAND Therapeutics, National Association of Healthcare Reimbursement, and Technic Solutions.

Paul Billings

Paul Billings, M.D., Chief Medical Officer, LIFE Technologies

Paul Billings, M.D., Chief Medical Officer, LIFE Technologies

Dr. Paul R. Billings is the first Chief Medical Officer of LIFE Technologies, a world leader in providing nucleic acid and other analytic tools for biomedical research and the delivery of personalized medicine. Prior to joining LIFE, Dr. Billings was the founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital in Mountain View, CA. From 2007-2009, Dr. Billings served as President, Chief Executive Officer and Director of CELLective Dx Corporation, a company sought to revolutionize cancer care through the provision of microfluidic products and services focused on circulating tumor cells. For five years until 2007, he was Senior Vice President and Senior Geneticist at Laboratory Corporation of America Holdings Inc (LH).Prior to joining LH, Dr. Billings was Deputy Chief of Staff and Chief of General Internal Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. Dr. Billings graduated with an AB in History summa cum laude from UC San Diego, received both his MD and PhD degrees from Harvard University.”

Stacy Feld

Stacy Feld, Partner, Physic Ventures

Stacy Feld, Partner, Physic Ventures

Stacy Feld, J.D., is a Partner at Physic Ventures. Stacy focuses on personalized health solutions to improve and transform care for the health consumer. Specifically, Stacy is interested in life science opportunities offering more precise prevention, diagnosis, and treatment of chronic disease. She is on the board of T2 Biosystems and an observer on the boards of On-Q-ity and Own.

Thomas A. Raffin

Thomas A. Raffin, M.D., General Partner, Telegraph Hill Partners

Thomas A. Raffin, M.D., General Partner, Telegraph Hill Partners

Tom spent 24 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, and Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics. He has written over 200 articles, chapters and books. Over the past two decades he has worked extensively in the healthcare and medical device sectors and is a co-founder of Rigel Pharmaceuticals. Tom has represented THP on the boards of AngioScore, Confirma (acquired by Merge), LDR, PneumRx and Freedom Innovations. He is an observer on the boards of Estech and Vidacare. Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and medical residency at the Peter Bent Brigham Hospital in Boston.

Vijay Lathi

Vijay Lathi, Managing Director, New Leaf Venture Partners

Vijay Lathi, Managing Director, New Leaf Venture Partners

Vijay Lathi is a Managing Director and concentrates primarily on our diagnostics and pharmaceuticals investments. Vijay joined Sprout in 1998 after working as an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology. Vijay is also a member of AiCHE.

    This entire site is licensed under Creative Commons Attribution-NoDerivs.   |   © Copyright PMWC International